1. Home
  2. ATAI vs XPER Comparison

ATAI vs XPER Comparison

Compare ATAI & XPER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATAI
  • XPER
  • Stock Information
  • Founded
  • ATAI 2018
  • XPER 1990
  • Country
  • ATAI Germany
  • XPER United States
  • Employees
  • ATAI N/A
  • XPER N/A
  • Industry
  • ATAI Biotechnology: Pharmaceutical Preparations
  • XPER Semiconductors
  • Sector
  • ATAI Health Care
  • XPER Technology
  • Exchange
  • ATAI Nasdaq
  • XPER Nasdaq
  • Market Cap
  • ATAI 444.7M
  • XPER 370.5M
  • IPO Year
  • ATAI 2021
  • XPER 2003
  • Fundamental
  • Price
  • ATAI $3.48
  • XPER $6.37
  • Analyst Decision
  • ATAI Strong Buy
  • XPER Strong Buy
  • Analyst Count
  • ATAI 3
  • XPER 3
  • Target Price
  • ATAI $11.67
  • XPER $13.00
  • AVG Volume (30 Days)
  • ATAI 8.9M
  • XPER 267.5K
  • Earning Date
  • ATAI 08-12-2025
  • XPER 08-06-2025
  • Dividend Yield
  • ATAI N/A
  • XPER N/A
  • EPS Growth
  • ATAI N/A
  • XPER N/A
  • EPS
  • ATAI N/A
  • XPER N/A
  • Revenue
  • ATAI $1,863,000.00
  • XPER $488,877,000.00
  • Revenue This Year
  • ATAI $423.05
  • XPER $0.50
  • Revenue Next Year
  • ATAI N/A
  • XPER $8.71
  • P/E Ratio
  • ATAI N/A
  • XPER N/A
  • Revenue Growth
  • ATAI 572.56
  • XPER N/A
  • 52 Week Low
  • ATAI $1.03
  • XPER $6.26
  • 52 Week High
  • ATAI $4.00
  • XPER $11.08
  • Technical
  • Relative Strength Index (RSI)
  • ATAI 60.69
  • XPER 21.23
  • Support Level
  • ATAI $3.06
  • XPER $7.56
  • Resistance Level
  • ATAI $3.70
  • XPER $7.59
  • Average True Range (ATR)
  • ATAI 0.27
  • XPER 0.22
  • MACD
  • ATAI 0.00
  • XPER -0.09
  • Stochastic Oscillator
  • ATAI 52.46
  • XPER 9.09

About ATAI ATAI Life Sciences N.V.

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.

About XPER Xperi Inc.

Xperi Inc is a consumer and entertainment technology company. Its offering comprises a portfolio of software and services. The company creates extraordinary experiences at home and on the go for millions of consumers around the world, enabling audiences to connect with content in a more intelligent, immersive, and personal way. Its business is divided into four categories based on the products delivered and customers served: Pay-TV, Consumer Electronics, Connected Car, and Platform Solutions. It generates the majority of its revenue from the Consumer Electronics segment. Its also have sales in Japan, Europe and Middle East, China, South Korea, Latin America, and Others.

Share on Social Networks: